CIBRN 2019 Q6: As of Jun 1 2019, the CADTH Common Drug Review and the pan-Canadian Oncology Drug Review (pCODR) will generally no longer review biosimilar drug submissions. CADTH states that the change reflects the way it deals with “traditional” small molecule generic drug products, which are also not typically subject to review. Do you agree with this change?


To view this question, please login.